EFMH
BMRN icon

E Fund Management (HK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

E Fund Management (HK)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
316
+80
+34% +$4.38K 0.01% 331
2026
Q1 		$13.3K Buy
+236
New +$13.8K 0.01% 297

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

E Fund Management (HK)'s BMRN Position: Q2 2026 in Review

E Fund Management (HK) increased its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q2 2026, buying an estimated $4.38K and bringing the position to 316 shares worth $18.1K. The position accounts for 0.01% of the portfolio, ranked #331.

E Fund Management (HK) first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • E Fund Management (HK) held 316 shares of BioMarin Pharmaceuticals worth $18.1K as of Q2 2026.
  • E Fund Management (HK) bought 80 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.38K.
  • BioMarin Pharmaceuticals made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #331 holding.
  • E Fund Management (HK) first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.